News | January 15, 2026
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Full approval will depend on verification of clinical benefit in a confirmatory trial
The expansion includes a larger technical and service team and increased local procurement
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
